诊断性血液生物标志物与轻度创伤性脑损伤神经影像学表现之间的关联
该单中心验证研究纳入104例疑似轻度创伤性脑损伤并接受头部CT的成人患者,伤后12小时内采血检测GFAP(>30 pg/mL)或UCH-L1(>360 pg/mL)。联合检测预测CT颅内损伤的敏感性为0.91(95%CI 0.59–1.00),特异性0.22(95%CI 0.14–0.31),阳性预测值0.12,阴性预测值0.95。假阳性病例(78%)年龄大于真阴性病例(中位72岁 vs 58.5岁)。GFAP/UCH-L1检测周转时间中位1.09小时,比头部CT快2小时。作者认为该检测有潜力作为CT前排除颅内损伤的初筛工具,但需大型多中心研究明确其对急诊资源利用、停留时间和成本效益的影响。
要点
- 104例疑似轻度创伤性脑损伤成人中,GFAP>30 pg/mL或UCH-L1>360 pg/mL预测CT颅内损伤敏感性0.91(95%CI 0.59–1.00)、特异性0.22(95%CI 0.14–0.31)。
- 联合检测阳性预测值仅0.12(95%CI 0.06–0.21),阴性预测值0.95(95%CI 0.76–1.00),低阳性预测值限制其单独确诊用途。
- 假阳性病例78%年龄大于真阴性病例(中位72岁 vs 58.5岁),高龄患者解读阳性结果需谨慎。
- GFAP/UCH-L1检测周转时间中位1.09小时,比头部CT的3.28小时快约2小时。
- 作者认为该血标志物有潜力作为CT前排除颅内损伤的初筛工具,但需大型多中心研究明确其影响。
适用人群与场景
- 单中心纳入104例疑似轻度创伤性脑损伤、接受头部CT评估的成人患者,2023年10月至2024年6月在一级创伤中心就诊。
诊断标准与关键阈值
- biomarker阳性阈值:GFAP>30 pg/mL或UCH-L1>360 pg/mL,外周血于伤后12小时内采集并在医院临床实验室处理。
研究设计与关键结果
- 单中心验证研究,n=104,83例生物标志物升高,11例CT发现颅内损伤。
- 联合血浆检测预测CT颅内损伤:敏感性0.91(95%CI 0.59–1.00),特异性0.22(95%CI 0.14–0.31),阳性预测值0.12(95%CI 0.06–0.21),阴性预测值0.95(95%CI 0.76–1.00)。
- 结果与既往研究一致:汇总敏感性0.97(95%CI 0.95–0.98),特异性0.28(95%CI 0.23–0.34)。
- 假阳性病例(78%)年龄大于真阴性病例:中位72岁(IQR 54–83)vs 58.5岁(IQR 38.25–66)。
- GFAP/UCH-L1检测周转时间中位1.09小时(IQR 0.87–1.65),头部CT为3.28小时(IQR 2.37–4.70),检测快2小时。
证据类型、等级与局限
- 证据类型:单中心临床验证研究。
- 局限:原文报告需大型多中心研究明确其对急诊资源利用、停留时间及急性和长期成本效益的影响。
对床旁实践的改变
- 作者认为血液生物标志物有潜力作为获取CT影像前排除颅内损伤的初筛工具。
- 作者指出需大型多中心研究明确其对急诊资源利用、停留时间以及患者和医疗系统急性和长期成本效益的影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Ann Emerg Med . 2026 Oct 27:S0196-0644(26)01286-2. doi: 10.1016/j.annemergmed.2026.08.731. Online ahead of print. ABSTRACT STUDY OBJECTIVE: Mild traumatic brain injury (mTBI) is a prevalent and resource-intensive injury in the emergency department (ED). The blood-based biomarkers glial fibrillary acidic protein (GFAP) and ubiquitin c-terminal hydrolase L1 (UCH-L1) have demonstrated diagnostic potential for acute structural brain injury. Our objective was to clinically validate a US Food and Drug Administration-approved plasma test to aid in the identification of intracranial injury in patients with mTBI presenting to the ED and assess its integration with existing protocols. METHODS: This single-center validation study enrolled 104 adult patients with suspected mTBI undergoing head computed tomography (CT) for evaluation between October 2023 and June 2024 at a Level I trauma center. Peripheral blood draw was completed within 12 hours postinjury and processed at the hospital clinical laboratory. Sensitivity, specificity, and predictive values for the test were calculated and compared with a standard clinical decision rule (Canadian Head CT Rule). ED length of stay and diagnostic turnaround times were examined. RESULTS: Within the cohort (n=104), 83 patients had elevated biomarker levels (GFAP >30 pg/mL or UCH-L1 >360 pg/mL), and 11 patients had intracranial injury identified on CT. The combination plasma test demonstrated high sensitivity (0.91 [95% confidence interval {CI} 0.59 to 1.00]) but low specificity (0.22 [95% CI 0.14 to 0.31]) for predicting intracranial injury on CT with low positive predictive value (0.12 [95% CI 0.06 to 0.21]) and high negative predictive value (0.95 [95% CI 0.76 to 1.00]). These findings are consistent with prior studies (pooled sensitivity 0.97 [95% CI 0.95 to 0.98]; specificity 0.28 [95% CI 0.23 to 0.34]). False-positive cases (78%) were older than true-negative cases (median 72 years [interquartile range (IQR) 54 to 83] versus 58.5 years [IQR 38.25 to 66]). Median turnaround time for the GFAP/UCH-L1 test was 2 hours faster than head CT (1.09 hours [IQR 0.87 to 1.65] versus 3.28 hours [IQR 2.37 to 4.70]). CONCLUSIONS: Blood biomarkers for mTBI have potential as an initial rule-out tool for intracranial injury prior to obtaining CT imaging; however, large multicenter studies are needed to clarify its impact on ED resource utilization, length of stay, and acute and long-term costs and benefits to patients and health care systems. PMID: 42949696 | DOI: 10.1016/j.annemergmed.2026.08.731
参考来源
- PubMed · Ann Emerg Med:Associations Between Diagnostic Blood-Based Biomarkers and Neuroimaging Findings in Mild Traumatic Brain Injury
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。